Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Crohn Disease (CD) Clear all

Conditions: Crohn's Disease
Interventions: Ontamalimab, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 73
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 62 more

Conditions: Crohn Disease (CD)
Interventions: DB-3Q, Placebo; Biological · Other
Lead sponsor: Direct Biologics, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Diet Modification
Interventions: Intermittent Reduced Calorie Diet (IRCD); Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions: Vedolizumab; Drug
Lead sponsor: Shaare Zedek Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Hartford, Connecticut • Morristown, New Jersey • New York, New York + 1 more

Conditions: Crohn Disease (CD), Crohn Disease
Interventions: Cranberry powder, Placebo; Drug · Dietary Supplement
Lead sponsor: Ana Maldonado-Contreras; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Crohn Disease
Interventions: Autologous stem cell transplant, Cyclophosphamide, Thymoglobulin, Methylprednisolone, Vedolizumab; Procedure · Drug
Lead sponsor: Aaron Etra; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease, IBD
Interventions: Brazikumab Induction Dose, Brazikumab Maintenance Dose; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Lincoln, California • Clearwater, Florida • Kissimmee, Florida + 6 more

Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 11
States / cities: San Francisco, California • Hartford, Connecticut • Atlanta, Georgia + 7 more

Conditions: Crohn's Disease (CD), Dysmenorrhea Primary
Interventions: Acetaminophen, Ibuprofen; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Crohn Disease
Interventions: Mirikizumab; Drug
Lead sponsor: Alimentiv Inc.; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Chicago, Illinois + 1 more

Conditions: Crohn Disease
Interventions: BI 706321, Ustekinumab, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 15
States / cities: Northridge, California • Hialeah, Florida • Inverness, Florida + 12 more

Conditions: Crohn's Disease
Interventions: H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group, Placebo Group; Drug
Lead sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Hamden, Connecticut • Lighthouse PT, Florida • Orlando, Florida

Conditions: Crohn Disease, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: IBD, Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD), Ultra Processed Food, Nutrition Assessment, DGBI
Interventions: Handout-Only Intervention, Handout + Video Intervention; Behavioral
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 10 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Crohn's Disease(CD)
Interventions: IBD-AID diet combined with Kate Farms Peptide 1.5, IBD-AID diet; Dietary Supplement · Other
Lead sponsor: Kate Farms Inc; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Crohn Disease
Interventions: Capsule Endoscopy; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 24
States / cities: Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more

Conditions: Crohn's Disease
Interventions: abatacept, placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more

Conditions: Crohn Disease
Interventions: Cimzia; Biological
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 20
States / cities: Lakewood, Colorado • Littleton, Colorado • New Port Richey, Florida + 16 more

Conditions: Crohn's Disease
Interventions: CROWN, CROWN Placebo; Drug
Lead sponsor: Prometheus Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 39
States / cities: Dothan, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 34 more

Conditions: Crohn Disease
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Rheumatoid Arthritis (RA), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions: Ketogenic diet, Carnivore (Lion) Diet; Behavioral
Lead sponsor: Fuller Research Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Crohn's Disease
Interventions: Colonoscopy; Procedure
Lead sponsor: Prometheus Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Ventura, California • Hamden, Connecticut + 2 more

Conditions: Crohn Disease
Interventions: CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin, ATG, Clofarabine, Melphalan, Total Body Irradiation, Rituximab; Device · Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 30 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Crohn's Disease
Interventions: Placebo for Risankizumab SC, Risankizumab IV, Placebo for Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 111
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more

Search by objective public record fields.

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

DB-3Q for the Treatment of Medically Refractory Crohn's Disease

Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease

Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases

Cranberry and Gut Health in Crohn's Disease

Autologous Stem Cell Transplant for Crohn's Disease

Open-label Extension Study of Brazikumab in Crohn's Disease

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)

Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

Characterization of CD Responders to Vedolizumab

Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD

Partial-enteral Nutrition Protocol for Crohn's Disease

Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.

A Study of Abatacept in Patients With Active Crohn's Disease

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy

Effect of SB CD on Chylomicron

Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease